{"version":"1.0","provider_name":"Tris Pharma","provider_url":"https:\/\/www.trispharma.com","title":"Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH\u2019s National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder - Tris Pharma","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"qYuN7zwv0X\"><a href=\"https:\/\/www.trispharma.com\/tris-pharma-awarded-five-year-grant-of-up-to-16-6m-from-the-nihs-national-institute-on-drug-abuse-to-advance-cebranopadol-for-the-treatment-of-opioid-use-disorder\/\">Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH\u2019s National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.trispharma.com\/tris-pharma-awarded-five-year-grant-of-up-to-16-6m-from-the-nihs-national-institute-on-drug-abuse-to-advance-cebranopadol-for-the-treatment-of-opioid-use-disorder\/embed\/#?secret=qYuN7zwv0X\" width=\"600\" height=\"338\" title=\"&#8220;Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH\u2019s National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder&#8221; &#8212; Tris Pharma\" data-secret=\"qYuN7zwv0X\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"[vc_row][vc_column][vc_column_text] \u2013\u00a0Funding will support preclinical through Phase 2 studies, with preclinical research\u00a0expected to initiate in Q4 2023 \u2013\u00a0 MONMOUTH JUNCTION, NJ, August 28, 2023 \u2013 Business Wire \u2013\u00a0Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced that the company has been awarded a grant expected to provide [&hellip;]"}